We are glad to announce that we have secured investment from Genesis Ventures. This pre-seed funding round, led by Genesis Ventures, signifies a significant milestone in our journey towards transforming cancer diagnostics.
1. Critical Need for Lung Cancer Testing
Lung cancer remains a global health challenge, ranking as the third most prevalent cancer worldwide and claiming the highest number of cancer-related deaths. Our innovative microRNA liquid biopsy offers a solution to this pressing issue by providing a simple blood test capable of detecting early-stage non-small cell lung carcinomas with enhanced accuracy and efficiency.
2. MicroRNA Technology
Our microRNA liquid biopsy represents a groundbreaking advancement in cancer screening. Our method offers superior sensitivity and specificity compared to traditional risk-factor screening methods. Our innovative approach has proven effective in our clinical study.
3. Funding and Our Future
As interest in venture capital grows for liquid biopsy technologies, Averywell stands out as a leader in microRNA-based diagnostics. Our focus on microRNA technology presents an exciting investment opportunity. Creating cutting-edge technology that relies on microRNA is changing the game in lung cancer screening and can potentially save countless lives.
We are proud to receive support from Genesis Ventures and strategic investors on our journey to redefine cancer diagnostics. We look forward to a future where early detection for lung cancer is cost-effective, highly accurate and equitable.
Check out this article to learn more about why Genesis Ventures invested in Averywell – Link